Zynerba Pharmaceuticals Inc (ZYNE) Shares Bought by Vanguard Group Inc

Vanguard Group Inc grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% in the 3rd quarter, according to the …

Zynerba Pharmaceuticals logoVanguard Group Inc grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 23.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 651,400 shares of the company’s stock after buying an additional 125,327 shares during the quarter. Vanguard Group Inc owned 3.69% of Zynerba Pharmaceuticals worth $5,316,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Zynerba Pharmaceuticals by 23.8% in the 3rd quarter. Vanguard Group Inc. now owns 651,400 shares of the company’s stock worth $5,316,000 after buying an additional 125,327 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Zynerba Pharmaceuticals in the 3rd quarter worth about $612,000. Jane Street Group LLC boosted its position in shares of Zynerba Pharmaceuticals by 44.6% in the 3rd quarter. Jane Street Group LLC now owns 35,555 shares of the company’s stock worth $290,000 after buying an additional 10,967 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Zynerba Pharmaceuticals in the 3rd quarter worth about $177,000. Finally, BlackRock Inc. boosted its position in shares of Zynerba Pharmaceuticals by 25.2% in the 3rd quarter. BlackRock Inc. now owns 298,355 shares of the company’s stock worth $2,435,000 after buying an additional 59,998 shares in the last quarter. Institutional investors own 15.32% of the company’s stock.

Several equities research analysts recently commented on the stock. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Cantor Fitzgerald set a $21.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 5th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, January 27th. Finally, HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.88.

ZYNE stock traded up $0.06 during trading on Tuesday, hitting $5.25. The stock had a trading volume of 5,588 shares, compared to its average volume of 1,093,379. Zynerba Pharmaceuticals Inc has a 1-year low of $2.75 and a 1-year high of $12.50. The company has a market capitalization of $91.48 million, a price-to-earnings ratio of -2.17 and a beta of 4.98.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Fairfield Current and is the property of of Fairfield Current. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.fairfieldcurrent.com/news/2019/02/12/zynerba-pharmaceuticals-inc-zyne-shares-bought-by-vanguard-group-inc.html.

Zynerba Pharmaceuticals Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Recommended Story: What are catch-up contributions?

Want to see what other hedge funds are holding ZYNE?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE).

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts